- Home
- ALLO vs RCKT Comparison
ALLO vs RCKT Comparison
Compare ALLO & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- RCKT
- Stock Information
- Founded
- ALLO 2017
- RCKT 1999
- Country
- ALLO United States
- RCKT United States
- Employees
- ALLO N/A
- RCKT N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- ALLO Health Care
- RCKT Health Care
- Exchange
- ALLO Nasdaq
- RCKT Nasdaq
- Market Cap
- ALLO 363.1M
- RCKT 328.6M
- IPO Year
- ALLO 2018
- RCKT N/A
- Fundamental
- Price
- ALLO $1.40
- RCKT $3.01
- Analyst Decision
- ALLO Strong Buy
- RCKT Buy
- Analyst Count
- ALLO 9
- RCKT 13
- Target Price
- ALLO $8.44
- RCKT $14.79
- AVG Volume (30 Days)
- ALLO 3.5M
- RCKT 3.4M
- Earning Date
- ALLO 08-06-2025
- RCKT 08-08-2025
- Dividend Yield
- ALLO N/A
- RCKT N/A
- EPS Growth
- ALLO N/A
- RCKT N/A
- EPS
- ALLO N/A
- RCKT N/A
- Revenue
- ALLO N/A
- RCKT N/A
- Revenue This Year
- ALLO N/A
- RCKT N/A
- Revenue Next Year
- ALLO $199.63
- RCKT $608.87
- P/E Ratio
- ALLO N/A
- RCKT N/A
- Revenue Growth
- ALLO N/A
- RCKT N/A
- 52 Week Low
- ALLO $0.86
- RCKT $2.19
- 52 Week High
- ALLO $3.78
- RCKT $25.40
- Technical
- Relative Strength Index (RSI)
- ALLO 54.41
- RCKT 46.12
- Support Level
- ALLO $1.21
- RCKT $3.03
- Resistance Level
- ALLO $1.31
- RCKT $3.22
- Average True Range (ATR)
- ALLO 0.11
- RCKT 0.21
- MACD
- ALLO 0.02
- RCKT 0.05
- Stochastic Oscillator
- ALLO 40.82
- RCKT 32.91
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.